Sorafenib Tosylate 475207-59-1 Manufacturer For Antitumor CAS NO.475207-59-1

Min.Order Quantity:: 10 Gram

Purity:: 99%

Port:: Wuhan

Payment Terms:: T/T,MoneyGram

Add to Inquiry Cart

Product Details

Keywords

99%min Sorafenib Tosylate
Sorafenib Tosylate Manufacturer
For Antitumor

Quick Details

ProName: Sorafenib Tosylate 475207-59-1 Manufac...
CasNo: 475207-59-1
Molecular Formula: C21H16ClF3N4O3.C7H8SO3
Appearance: White Powder
Application: It Can Be Used As Pharmaceutical Inte...
DeliveryTime: 2-4 days after confirming your payment...
PackAge: 100g/ bag, 2 kg/ bag, 25kg/ carton or ...
Port: Wuhan
ProductionCapacity: 10000 Metric Ton/Month
Purity: 99%
Storage: Store in sealed containers at cool & d...
Transportation: By DHL, TNT, FedEx, HKEMS, UPS, Etc
LimitNum: 10 Gram

Superiority

advantages:

hubei xinrunde chemical co., ltd is a renowned pharmaceutical manufacturer. we can offer high quality products at competitive price in quick delivery with 100% custom pass guaranteed. never stop striving to offer our best service is our philosophy. we have flexible and untraceable payment terms. as a leading manufacture, our products have been exported to germany, norway, poland, finland, spain, uk, france, russia, usa, brazil, mexico, australia, japan, korea, thailand, indonesia, uruguay and many other countries.

1. quality.every batch of steroid powders have tobetested by our qc(quality control) before they are allowed to sell.

2. delivery we have stock, so we can delivery quickly at the very day when receive the payment. within 24 hours after receiving the payment lead time 4 or 7 days.

3. discreet package safelyand professionally disguised package guaranteed. for your safety and to insure delivery all products will be packed in a discreet way to prevent any suspicions, no steroids related name will appear on the parcels. high successful delivery rate.

4. warm after-sale service any of your question would be solved for the first as soon as possible.

Details

sorafenib tosylate basic information

indications and usage mechanisms of action clinical research adverse reactions

product name:	sorafenib tosylate
synonyms:	sorafenib tosylate;sorafenib & its intermediates;sorafinib mesylate;4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-n-(5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide monomethanesulfonate;sorafenib tosylate(bay 43-9006,nexavar);2-pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-n-methyl-, 4-methylbenzenesulfonate;sorafenib tosylate (nexavar);sorafenib (nexavar)
cas:	475207-59-1
mf:	c21h16clf3n4o3.c7h8so3
mw:	637.03
einecs:	1592732-453-0
product categories:	bay 43-9006;inhibitors;mapk
mol file:	mol file

sorafenib tosylate chemical properties

cas database reference

475207-59-1(cas database reference)

safety information

risk statements	36/37/38
safety statements	28-26

sorafenib tosylate usage and synthesis

indications and usage	sorafenib tosylate is a new type of multi-target antitumor drug, was developed by the german bayer pharmaceuticals, and displayed expansive antitumor activity in preclinical animal tests. sorafenib tosylate is mainly used in advanced liver cancer treatment and is well tolerated.
mechanisms of action	sorafenib tosylate can simultaneously affect tumor cells and tumor blood vessels. it has a double antitumor effect: it can block the cell signal transduction pathways mediated by raf/mek/erk to directly inhibit tumor cell growth, while also inhibiting vegf and platelet derived growth factors (pdgf) receptors to prevent the formation of new tumor blood vessels, thus indirectly inhibiting tumor cell growth.
clinical research	in a stage three randomized clinical study of american and european treatments for advanced kidney cancer, 903 cases advanced kidney patients who had experienced one unsuccessful systematic treatment (biological immunity or chemotherapy) were randomly split into two groups. one group received sorafenib tosylate, while the other received a placebo. mid-term analysis found already 222 deaths and the objective efficacy of the two groups to be 10% and 2%, while 74% and 53% of patients had stabilized conditions. the sorafenib tosylate group’s survival period was longer than that of the placebo group, with the risk ratio as 0.72. however, this different does not have statistical significance, as this is only a mid-term analysis, and final analysis after treatment will yield the correct survival period comparison. 602 advanced liver cancer patients selected from the usa, europe, australia, and other countries and areas, who did not receive systematic treatment, were included in a study. results showed that compared to the placebo, taking sorafenib tosylate could extend their total survival period of patients with late stage or primary liver cancer by about 44% and their extend disease progression period by about 73%.
adverse reactions	manageable diarrhea, rashes, fatigue, hand-foot syndrome, hypertension, alopecia, nausea, vomiting, and loss of appetite.
uses	sorafenib tosylate (bay 43-9006, nexavar) is a small molecular inhibitor of vegfr, pdgfr, c-raf and b-raf with ic50s of 18 nm, 10 nm, 3 nm and 15 nm, respectively.
uses	sorafenib tosylate (bay 43-9006) is a multikinase inhibitor of raf-1, b-raf and vegfr-2 with ic50 of 6 nm, 22 nm and 90 nm, respectively
uses	an inhibitor of flk-1 (vegfr), pdgfr and raf kinases.